Korro Bio, Inc. (KRRO)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-09-29. ClinicalTrials.gov
Dilution Risk
HIGH DILUTION RISKDilution score: 67/100 (HIGH), 3.9 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 16.58% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Korro to Participate in Upcoming Investor Conferences
- Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- Korro Bio, Inc. (KRRO) Upgraded to Buy: What Does It Mean for the Stock?
- Korro Bio, Inc. (KRRO) Soars 17.6%: Is Further Upside Left in the Stock?
- One Korro Bio Insider Raised Stake By 19% In Previous Year
- Korro to Present at the 2026 Jefferies Global Healthcare Conference
- Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Korro Bio, Inc..
Full KRRO Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.